Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  brentuximab vedotin
Find trials that include:  Any drugs shown
Results 1-25 of 33 for your search:
Start Over
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: C25001, NCI-2012-01066, 2010-024215-14, NCT01578499
Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: C25003, NCI-2012-03101, 12/LO/1950, 2011-005450-60, JapicCTI-142491, U1111-1161-4937, NCT01712490
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: SGN35-014, NCI-2013-00462, 2012-002751-42, NCT01777152
Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients with Newly Diagnosed Hodgkin Lymphoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Supportive care, Treatment
Age: 18 and younger
Trial IDs: AHOD1331, NCI-2014-01223, NCT02166463
Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 18
Trial IDs: C25002, NCI-2012-01146, 2011-001240-29, U1111-1158-2613, NCT01492088
Brentuximab Vedotin and Bendamustine Hydrochloride in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: AAAJ5050, NCI-2012-01926, NCT01657331
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients with Stage II-IV HIV-Associated Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AMC-085, NCI-2013-00046, 085, 2014-003678-18, PAMC-085_A05PAMDREVW01, NCT01771107
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients with Relapsed or Refractory Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 to 30
Trial IDs: AHOD1221, NCI-2013-00107, COG-AHOD1221, NCT01780662
Brentuximab Vedotin and Rituximab in Treating Patients with Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 12H09, NCI-2012-03090, STU00072695, NCT01805037
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Untreated Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma or Gray Zone Lymphomas
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 17413, NCI-2013-02359, 818280, NCT01994850
Brentuximab Vedotin with or without Azacitidine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0706, NCI-2014-01114, NCT02096042
Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9111, NCI-2014-01782, NCT02227199
Mocetinostat and Brentuximab Vedotin in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-232, NCI-2015-00780, NCT02429375
Brentuximab Vedotin in Treating Patients with Non-Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2010-0914, NCI-2011-01045, NCT01352520
Brentuximab Vedotin before Autologous Stem Cell Transplant in Treating Patients with Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 11051, NCI-2011-01135, 117313, NCT01393717
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients with Previously Untreated Stage II-IV Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: NU 11H01, NCI-2011-00684, NCT01476410
Combination Chemotherapy and Brentuximab Vedotin in Treating Patients with Stage I-II Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 to 60
Trial IDs: LCCC 1115, NCI-2013-00975, 12-0303, NCT01578967
A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: SGN35-015, NCI-2012-02209, NCT01716806
Brentuximab Vedotin, Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients with Stage IIB-IVB Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and under
Trial IDs: HLHR13, NCI-2013-01123, NCT01920932
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: SGN35-017, NCI-2013-01726, NCT01925612
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients with Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: ANHL12P1, NCI-2013-02167, COG-ANHL12P1, NCT01979536
Brentuximab Vedotin Maintenance after Donor Stem Cell Transplant in Treating Patients with Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 to 65
Trial IDs: 2013-0351, NCI-2014-01593, NCT02169505
Brentuximab Vedotin, Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-040, NCI-2013-01114, NCT01830777
Ipilimumab and Brentuximab Vedotin in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E4412, NCI-2013-01275, NCT01896999
Brentuximab Vedotin and Lenalidomide in Treating Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201404056, NCI-2014-01036, 14-X032, NCT02086604
Start Over